$30 Billion and Counting (4.29.2022)
Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.
Pre-exposure Prophylaxis for COVID-19 (4.22.22)
Dr. Jack Cush discusses the news and recent journal reports from last weeks RheumNow.com, and answers viewer questions from #ACA - Ask Cush Anything.
COVID-19 Vaccination Uptake and Perceptions in Rheumatic Patients
Putman et al has reported vaccine survey results from the COVID-19 Global Rheumatology Alliance (C19-GRA) in Lancet Rheumatology showing the uptake and vaccine hesitancy among people with rheumatic diseases (RMD).
Evusheld as Protective Therapy in High Risk COVID-19 Patients
A single dose of the monoclonal-antibody AZD7442 (combination of tixagevimab and cilgavimab) has been shown to be safe and effective as prophylaxis against COVID-19 infection in high risk individuals who tested positive for COVID-19.
Male vs. Female Responders (4.15.2022)
Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic.
Consensus Best Practices for Virtual Care in Rheumatology
The Canadian Rheumatology Association’s (CRA) Telehealth Working Group (TWG) has developed a series of best practice statements for the virtual care in adult and pediatric rheumatology patients.
ACR Fellow Training Subcommittee Report on Pandemic Experiences
Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training.
RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)
Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.
FDA Authorizes 2nd Booster for Older and Immunocompromised Individuals
FDA
Today, the U.S. Food and Drug Administration authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals.
Are Shoulder Conditions Incited by Vaccination?
A retrospective cohort study from Kaiser Permanente Southern California intramuscular vaccination given between 2016 and 2017 shows a small but significant increase in shoulder conditions, reported as an adverse event (AE) following intramuscular vaccination in the deltoid muscle.
Consequences of TNF inhibition (3.18.2022)
This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April! This and more as Dr.
Baricitinib’s COVID-19 Efficacy in the RECOVERY Trial
Pre-print results of the RECOVERY Trial has shown that when baricitinib (BAR) is given to hospitalized severe COVID-19 patients, it results in significantly less mortality.
Social
in 2022 COVID slid from the #3 to the #4 cause of death in USA, accounting for nearly a quarter million deaths, a 47 percent decrease from the 462,193 Covid-related deaths in 2021. Most COVID deaths occured in the first few mos of 2022 https://t.co/qervCp0P87 https://t.co/WN7DvsFhNC
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 6 months ago
COVID had a significant effect on mental health of inflammatory rheumatic Dz (IRDs) pts. UK NHS survey of 639 IRD (70% RA, 16% PsA) saw 40% w/ mod/severe pandemic impact on physical & mental health; 29% w/ depression, 22% anxiety; affecting Women>males https://t.co/kcAwa2Lks2 https://t.co/R6tk2aOrGQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Industry Payments to Rheums Dropped During COVID
Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that payments from industry dried up as well.
https://t.co/jsxw23tTyY https://t.co/5PiaRpiSa4
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Anakinra Phase 2/3 study in severe hosp. COVID-19 pts (5/20-3/21) w/ pneumonia & hyperinflammation (incr levels IL-6, ferritin, CRP, LDH). 179 pt Rx w/ ANA or SOC - d15 need for Mech ventilation was 77% ANAK v 86% SoC (NS; RR 0.90; 0.77-1.04) https://t.co/CFcI1qTsU2 https://t.co/wAj4pHN5Dh
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Paxlovid (Nirmatrelvir-Ritonavir) should be used w/in 5d of COVID Sxs onset. Drug interactions include: steroids, anticoagulants (Eliquis, Xarelto, warfarin), Flomax, Calcium channel blockers, benzodiazepines. https://t.co/VZpS1z3OGR https://t.co/hR6JAJ3BBO
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
Great #RNL2023 Plenary with "Miracle Larry" after 128 days in hospital for COVID-19, on 3-year anniversary of going into coma
"I am the expert on what this virus can do. I don't want the world to ever forget"
@RheumNow https://t.co/kTuDXDhTtQ
Eric Dein @ericdeinmd ( View Tweet )
1 year 8 months ago
Tremendously emotional (and unfiltered) first person account of his fight with COVID-19 by Miracle Larry who thanked our Dr. Cush @RheumNow for his ingenuity in fighting COVID-19, thanking healthcare workers for all they do, and reminding us to be empathic.
#RNL2023 https://t.co/i0D7r8dR8n
Robert B Chao, MD @doctorRBC ( View Tweet )
1 year 8 months ago
Lancet metanalysis shows pts infected w/ SARS-CoV2 are conferred very high degree of re-infx from pre-omicron variants, even after 40 weeks. Protection was lower for omicron BA.1 & declined over time. Protection from severe Dz was high for all variants. https://t.co/RNgYVWQfNo https://t.co/J8U37NYXPP
Links:
Dr. John Cush @RheumNow ( View Tweet )
1 year 8 months ago
